Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Japan’s Eisai and US biotech major Biogen have announced that the latest findings demonstrating the benefits of continuous ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...

Eisai (OTCPK:ESALF) and Eli Lilly (NYSE:LLY) on Wednesday announced data from long-term extension studies for their ...

Eisai and Biogen's Alzheimer's drug Leqembi continues to show promise in slowing disease progression, with no new safety issues observed over four years. The injectable form of Leqembi is under U.S.

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

Eisai now expects Leqembi sales to total JPY 42.5 billion for the period, down from JPY 56.5 billion announced in May. Leqembi sales for the first half of Eisai's FY2024 amounted to JPY 16.3 ...

Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion Nov. 07, 2024 11:19 PM ET Barnes Group Inc. (B), BIOA ...